Guardant Health Stock Forecast, Price & News

Guardant Health (NASDAQ:GH) Frequently Asked Questions

Is Guardant Health a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Guardant Health stock.
View analyst ratings for Guardant Health or view top-rated stocks.

How has Guardant Health's stock been impacted by COVID-19?

Guardant Health's stock was trading at $62.95 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GH stock has increased by 51.5% and is now trading at $95.39.
View which stocks have been most impacted by COVID-19.

When is Guardant Health's next earnings date?

Guardant Health is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Guardant Health.

How were Guardant Health's earnings last quarter?

Guardant Health, Inc. (NASDAQ:GH) released its earnings results on Thursday, November, 4th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.90) by $0.16. The business earned $94.80 million during the quarter, compared to analyst estimates of $92.59 million. Guardant Health had a negative net margin of 118.80% and a negative trailing twelve-month return on equity of 44.55%. The company's revenue was up 26.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.78) EPS.
View Guardant Health's earnings history.

What guidance has Guardant Health issued on next quarter's earnings?

Guardant Health updated its FY 2021 earnings guidance on Thursday, December, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $360 million-$370 million, compared to the consensus revenue estimate of $366.68 million.

What price target have analysts set for GH?

11 analysts have issued 12-month target prices for Guardant Health's shares. Their forecasts range from $155.00 to $190.00. On average, they expect Guardant Health's stock price to reach $169.90 in the next year. This suggests a possible upside of 78.1% from the stock's current price.
View analysts' price targets for Guardant Health or view top-rated stocks among Wall Street analysts.

Who are Guardant Health's key executives?

Guardant Health's management team includes the following people:

• Helmy Eltoukhy, Chairman & Co-Chief Executive Officer (LinkedIn Profile)
• AmirAli H. Talasaz, President, Co-Chief Executive Officer & Director
• Michael Bell, Chief Financial Officer
• Darya Chudova, Senior Vice President-Technology
• Kumud Kalia, Chief Information Officer

What is Helmy Eltoukhy's approval rating as Guardant Health's CEO?

52 employees have rated Guardant Health CEO Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among Guardant Health's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Guardant Health's key competitors?

Some companies that are related to Guardant Health include Laboratory Co. of America (LH), Quest Diagnostics (DGX), Natera (NTRA), Elekta AB (publ) (EKTAY), Invitae (NVTA), Veracyte (VCYT), Fulgent Genetics (FLGT), CareDx (CDNA), RadNet (RDNT), Burning Rock Biotech (BNR), Castle Biosciences (CSTL), Genetron (GTH), Personalis (PSNL), Renalytix AI (RNLX) and DermTech (DMTK).
View all of GH's competitors.

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Square (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

When did Guardant Health IPO?

(GH) raised $200 million in an initial public offering on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

What is Guardant Health's stock symbol?

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Who are Guardant Health's major shareholders?

Guardant Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Morgan Stanley (5.47%), BlackRock Inc. (5.48%), Capital Research Global Investors (5.20%), Viking Global Investors LP (4.82%), Coatue Management LLC (2.76%) and Credit Suisse AG (1.76%). Company insiders that own Guardant Health stock include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Samir Kaul, Stanley J Meresman and Stanley J Meresman.
View institutional ownership trends for Guardant Health.

Which institutional investors are selling Guardant Health stock?

GH stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Deutsche Bank AG, Blue Water Life Science Advisors LLC, Jane Street Group LLC, Janus Henderson Group PLC, Polar Capital Holdings Plc, Bank of Nova Scotia, and FIL Ltd. Company insiders that have sold Guardant Health company stock in the last year include Amirali Talasaz, Helmy Eltoukhy, Ian T Clark, Samir Kaul, and Stanley J Meresman.
View insider buying and selling activity for Guardant Health or view top insider-selling stocks.

Which institutional investors are buying Guardant Health stock?

GH stock was acquired by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Morgan Stanley, Viking Global Investors LP, American Century Companies Inc., Moore Capital Management LP, Macquarie Group Ltd., Pura Vida Investments LLC, and Coatue Management LLC.
View insider buying and selling activity for Guardant Health or or view top insider-buying stocks.

How do I buy shares of Guardant Health?

Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Guardant Health's stock price today?

One share of GH stock can currently be purchased for approximately $95.39.

How much money does Guardant Health make?

Guardant Health has a market capitalization of $9.70 billion and generates $286.73 million in revenue each year. The company earns $-253.78 million in net income (profit) each year or ($4.05) on an earnings per share basis.

How many employees does Guardant Health have?

Guardant Health employs 864 workers across the globe.

What is Guardant Health's official website?

The official website for Guardant Health is www.guardanthealth.com.

Where are Guardant Health's headquarters?

Guardant Health is headquartered at 505 PENOBSCOT DR., REDWOOD CITY CA, 94063.

How can I contact Guardant Health?

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company can be reached via phone at (855) 698-8887, via email at [email protected], or via fax at 888-974-4258.